CoChat
Sign Up
Cited by 101

The DOI matches its Crossref record.

Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer

Duan, Weili, Du, Lutao, Jiang, Xiumei, Wang, Rui, Yan, Suzhen, Xie, Yujiao, Yan, Keqiang, Wang, Qingliang, Wang, Lili, Zhang, Xin, Pan, Hongwei, Yang, Yongmei, Wang, Chuanxin·2016·Oncotarget
DOI 10.18632/oncotarget.12880PMC PMC5346682
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12880

Cites

Statistics

Figures

Figure 1 Expression levels of serum MEG3, SNHG16 and MALAT1 and their expression in paired serum and tissue Expression levels of serum MEG3 (A), SNHG16 (B) and MALAT1 (C) in Healthy vs. Benign disease (p > 0.05), Healthy vs. BCs (p < 0.01) and Benign disease vs. BCs comparisons (p < 0.01). The scatter plot showed the relative expression of MEG3 (D), SNHG16 (E) and MALAT1 (F) in BC tissues and serum. Date were presented as 2−ΔΔCt.
Figure 1 Expression levels of serum MEG3, SNHG16 and MALAT1 and their expression in paired serum and tissue Expression levels of serum MEG3 (A), SNHG16 (B) and MALAT1 (C) in Healthy vs. Benign disease (p > 0.05), Healthy vs. BCs (p < 0.01) and Benign disease vs. BCs comparisons (p < 0.01). The scatter plot showed the relative expression of MEG3 (D), SNHG16 (E) and MALAT1 (F) in BC tissues and serum. Date were presented as 2−ΔΔCt.CC BY · PubMed Central
Figure 2 Diagnostic performance of selected lncRNAs for BC patients versus controls Receiver operating characteristics (ROC) curve analysis for detection of BC using MEG3 (A), SNHG16 (B) and MALAT1 (C) in BC patients and controls in training set.
Figure 2 Diagnostic performance of selected lncRNAs for BC patients versus controls Receiver operating characteristics (ROC) curve analysis for detection of BC using MEG3 (A), SNHG16 (B) and MALAT1 (C) in BC patients and controls in training set.CC BY · PubMed Central
Figure 3 Diagnostic performance of three-lncRNA panel and urine cytology for the detection of BC Receiver operating characteristics curve (ROC) analysis using three-lncRNA panel for the detection of BC in training set (A) and in validation set (B); ROC curves showing the diagnostic performance of the three-lncRNA panel for Ta (C), T1 (D) and T2–T4 (E) in validation set; ROC curve analysis for the detection of BC using urine cytology for the detection of BC with all stages (F), Ta (G), T1 (H), and T2–T4 (I) in validation set.
Figure 3 Diagnostic performance of three-lncRNA panel and urine cytology for the detection of BC Receiver operating characteristics curve (ROC) analysis using three-lncRNA panel for the detection of BC in training set (A) and in validation set (B); ROC curves showing the diagnostic performance of the three-lncRNA panel for Ta (C), T1 (D) and T2–T4 (E) in validation set; ROC curve analysis for the detection of BC using urine cytology for the detection of BC with all stages (F), Ta (G), T1 (H), and T2–T4 (I) in validation set.CC BY · PubMed Central
Figure 4 Recurrence prediction of MEG3 expression Kaplan-Meier curve showed that low level of serum MEG3 was associated with a worse recurrence-free survival in NMIBC patients in validation set.
Figure 4 Recurrence prediction of MEG3 expression Kaplan-Meier curve showed that low level of serum MEG3 was associated with a worse recurrence-free survival in NMIBC patients in validation set.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 33

  1. Jemal, 2016, Cancer statistics, 2016, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 · DOI · Paper page
  2. Feldman, 2009, Bladder cancer, Lancet, 374, 239, 10.1016/S0140-6736(09)60491-8 · DOI
  3. Belldegrun, 2001, Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma, Rev Urol, 3, 85
  4. Verjovski-Almeida, 2012, Perspectives of Long Non-Coding RNAs in Cancer Diagnostics, Front Genet, 3, 32
  5. Lo, 2002, Stability of endogenous and added RNA in blood specimens, serum, and plasma, Clin Chem, 48, 1647, 10.1093/clinchem/48.10.1647 · DOI
  6. Zhang, 2015, Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer, Sci Rep, 5, 11516, 10.1038/srep11516 · DOI
  7. Cao, 2015, Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma, Mol Cancer, 14, 3, 10.1186/1476-4598-14-3 · DOI
  8. Du, 2015, Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls, Int J Cancer, 137, 1128, 10.1002/ijc.29484 · DOI
  9. Qiu, 2013, Downregulated MEG3 activates autophagy and increases cell proliferationin bladder cancer, Mol Biosyst, 9, 407, 10.1039/c2mb25386k · DOI
  10. Li, 2011, ncRAN, a newly identified long noncoding RNA, enhances human bladdertumor growth, invasion, and survival, Urology, 77, 510
  11. Qiu, 2012, Upregulated MALAT-1 contributes to bladder cancer cell migration byinducing epithelial-to-mesenchymal transition, Mol Biosyst, 8, 2289, 10.1039/c2mb25070e · DOI
  12. Huang, 2015, Inducing cell growth arrest and apoptosis by silencing long non-codingRNA PCAT-1 in human bladder cancer, Tumour Biol, 36, 7685, 10.1007/s13277-015-3490-3 · DOI
  13. Weng, 2014, Long noncoding RNA GHET1 promotes the development of bladder cancer, Int J Clin Exp Pathol, 7, 7196
  14. Qiu, 2013, Long non-coding RNA H19 increases bladder cancer metastasis byassociating with EZH2 and inhibiting E-cadherin expression, Cancer Lett, 333, 213, 10.1016/j.canlet.2013.01.033 · DOI
  15. Lin, 2013, linc-UBC1 physically associates with polycomb repressive complex 2(PRC2) and acts as a negative prognostic factor for lymph nodemetastasis and survival in bladder cancer, Biochim Biophys Acta, 1832, 1528, 10.1016/j.bbadis.2013.05.010 · DOI
  16. Du, 2015, Increased expression of SPRY4-IT1 predicts poor prognosis andpromotes tumor growth and metastasis in bladder cancer, Int J Clin Exp Pathol, 8, 1954
  17. Cai, 2013, Long intergenic non-coding RNA TUG1 is overexpressed in urothelialcarcinoma of the bladder, J Surg Oncol, 107, 555, 10.1002/jso.23264 · DOI
  18. Chen, 2012, Long non-coding RNA UCA1 regulated cell cycle distribution via CREBthrough PI3-K dependent pathway in bladder carcinoma cells, Gene, 496, 8, 10.1016/j.gene.2012.01.012 · DOI
  19. Xie, 2014, Genome-wide screening and identification of long noncoding RNAs and their interaction with protein coding RNAs in bladder urothelial cellcarcinoma, Cancer Lett, 349, 77, 10.1016/j.canlet.2014.03.033 · DOI
  20. Qiu, 2013, Downregulation of GAS5 promotes bladder cancer cell proliferation, partlyby regulating CDK6, PLoS One, 8, e73991, 10.1371/journal.pone.0073991 · DOI
  21. Schulz, 2014, Concomitant downregulation of the imprinted genes DLK1 and MEG3 at14q32. 2 by epigenetic mechanisms in urothelial carcinoma, Clin Epigenetics, 6, 29, 10.1186/1868-7083-6-29 · DOI
  22. Du, 2015, Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overallsurvival for colorectal cancer patients, Mol Carcinog, 54, 742, 10.1002/mc.22137 · DOI
  23. Liu, 2014, TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12, Clin Cancer Res, 20, 1531, 10.1158/1078-0432.CCR-13-1455 · DOI
  24. Zhu, 2014, MALAT1 promotes cell proliferation in gastric cancer by recruitingSF2/ASF, Biomed Pharmacother, 68, 557, 10.1016/j.biopha.2014.04.007 · DOI
  25. Zhao, 2013, Long noncoding RNA MALAT-1 is a new potential therapeutic target forcastration resistant prostate cancer, J Urol, 190, 2278, 10.1016/j.juro.2013.07.001 · DOI
  26. Cai, 2014, High expression of lncRNA MALAT1 suggests a biomarker of poorprognosis in colorectal cancer, Int J Clin Exp Pathol, 7, 3174
  27. Reinhold, 2001, Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum, Clin Chem, 47, 1488, 10.1093/clinchem/47.8.1488 · DOI
  28. Stoorvogel, 2013, Extracellular vesicles: exosomes, microvesicles, and friends, J Cell Biol, 200, 373, 10.1083/jcb.201211138 · DOI · Paper page
  29. Guo, 2015, Plasma long noncoding RNA protected by exosomes as a potential stablebiomarker for gastric cancer, Tumour Biol, 36, 2007, 10.1007/s13277-014-2807-y · DOI
  30. Tewari, 2011, Argonaute2 complexes carry a population of circulating microRNAsindependent of vesicles in human plasma, Proc Natl Acad Sci USA, 108, 5003, 10.1073/pnas.1019055108 · DOI · Paper page
  31. Ochiya, 2010, Secretory microRNAs as a versatile communication tool, Commun Integr Biol, 3, 478, 10.4161/cib.3.5.12693 · DOI
  32. Guo, 2015, Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer, Tumour Biol, 36, 4851, 10.1007/s13277-015-3139-2 · DOI
  33. Sun, 2016, The aberrant expression of MEG3 regulated by UHRF1 predicts theprognosis of hepatocellular carcinoma, Mol Carcinog, 55, 209, 10.1002/mc.22270 · DOI

Cited by

Sorted by citations

Metadata

Authors
Duan, W., Du, L., Jiang, X., Wang, R., Yan, S., Xie, Y., Yan, K., Wang, Q., Wang, L., Zhang, X., Pan, H., Yang, Y., & Wang, C.
Affiliations
  • Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China
  • Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China
  • Department of Medical Affairs Management, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2016-10-25
Volume
7
Issue
48
Pages
78850-78858
ISSN
1949-2553
DOI
10.18632/oncotarget.12880
PMC
PMC5346682
Cited by
101
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review